The CHMP recommends conditional marketing authorization of REGN's linvoseltamab to treat adults with relapsed and refractory multiple myeloma.

In spite of recent advances in the management of multiple myeloma, cure has been elusive, with efforts to improve long-term ...

New Delhi: The Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organisation (CDSCO) has ...

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion ...

Kangpu Biopharma receives China NMPA’s IND approval for KPG-818 to treat relapsed/refractory multiple myeloma: Hefei, China Saturday, March 1, 2025, 14:00 Hrs [IST] Kangpu Bioph ...

Feb. 4, 2025 — Research has shown that a potential new targeted therapy for childhood brain cancer is effective in infiltrating and killing tumor cells in ... How Healthy Stem Cells Turn Into Or ...

Researchers from Osaka University develop a new technology that allows in-depth analysis of immune system controlDeveloping ...

Paris: Sanofi has announced that the Ministry of Health, Labour and Welfare (MHLW) in Japan has approved Sarclisa, in ...

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human ...

Feb. 26, 2025 — Researchers investigating the role of the protein CD44 in obesity and metabolic health found that CD44-deficient mice stayed lean even on a high-fat diet, while the control mice ...

The expansion of the advanced therapy medicinal products market is primarily fueled by the increasing incidence of chronic diseases. The rising prevalence of genetic disorders and cancer, along ...